SUBCUTANEOUS IGF-1 IS NOT BENEFICIAL IN 2-YEAR ALS TRIAL Reply

Letter/Communication

E. J. Sorenson, A. J. Windbank, J. N. Mandrekar, W. R. Bamlet, S. H. Appel, C. Armon, P. E. Barkhaus, P. Bosch, K. Boylan, W. S. David, …

Neurology, Vol.73(15), pp.1247-1248

10/13/2009

View Online

Clinical Neurology

Life Sciences & Biomedicine

Neurosciences & Neurology

Science & Technology

Title: Subtitle: SUBCUTANEOUS IGF-1 IS NOT BENEFICIAL IN 2-YEAR ALS TRIAL Reply
Creators: E. J. Sorenson
A. J. Windbank
J. N. Mandrekar
W. R. Bamlet
S. H. Appel
C. Armon
P. E. Barkhaus
P. Bosch
K. Boylan
W. S. David
E. Feldman
J. Glass
L. Gutmann - University of Iowa, Neurology
J. Katz
W. King
C. A. Luciano
L. F. McCluskey
S. Nash
D. S. Newman
R. M. Pascuzzi
E. Pioro
L. J. Sams
S. Scelsa
E. P. Simpson
S. H. Subramony
E. Tiryaki
C. A. Thornton
Resource Type: Letter/Communication
Publication Details: Neurology, Vol.73(15), pp.1247-1248
Publisher: Lippincott Williams & Wilkins
ISSN: 0028-3878
eISSN: 1526-632X
Number of pages: 2
Language: English
Date published: 10/13/2009
Academic Unit: Neurology
Record Identifier: 9984302207702771

11 Record Views